By combining the targeting capabilities of TM4SF5 with the therapeutic potential of MACC1 inhibition, we aim to develop a novel, targeted therapeutic strategy that holds promise for improving the treatment of CRC patients [16]. This evidence concerns the gene TM4SF5 and colorectal carcinoma.